Check for updates

OPEN ACCESS

EDITED BY Sawsan A. Zaitone, University of Tabuk, Saudi Arabia

REVIEWED BY Dina Khodeer, Suez Canal University, Egypt Samah M. Elaidy, Suez Canal University, Egypt

*CORRESPONDENCE Bin Zhang ⊠ zhangb87@mail2.sysu.edu.cn

RECEIVED 16 June 2024 ACCEPTED 19 August 2024 PUBLISHED 12 September 2024

CITATION

Li J, Jiang C, Wu L, Tian J and Zhang B (2024) Dietary selenium intake and sarcopenia in American adults. *Front. Nutr.* 11:1449980. doi: 10.3389/fnut.2024.1449980

COPYRIGHT

© 2024 Li, Jiang, Wu, Tian and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Dietary selenium intake and sarcopenia in American adults

Jianfen Li¹, Chaohui Jiang², Lingfeng Wu¹, Jiangyan Tian¹ and Bin Zhang^{3,4*}

¹Department of General Practice, Jiangmen Central Hospital, Jiangmen, China, ²Department of Hematopathology, Jiangmen Central Hospital, Jiangmen, China, ³Department of Cardiovascular Disease and Clinical Experimental Center, Jiangmen Central Hospital, Jiangmen, China, ⁴Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Background: The relationship between dietary selenium intake and sarcopenia remains poorly understood. Therefore, this study investigates the associations between dietary selenium intake and sarcopenia among American adults.

Methods: This cross-sectional study analyzed data from 19,696 participants in the National Health and Nutrition Examination Survey (NHANES) for the periods 1999–2006 and 2011–2018. Appendicular muscle mass, assessed using dualenergy x-ray absorptiometry and adjusted for body mass index, was used as a marker for sarcopenia. Dietary selenium intake was evaluated using the 24-h dietary recall system, and the study accounted for the complex sampling methodology and incorporated dietary sample weights in the analysis.

Results: Among the 19,696 participants, the prevalence of sarcopenia was found to be 8.46%. When compared to the lowest quintile of dietary selenium intake (Q1, <80.10 µg/day), the odds ratios for sarcopenia in the second quintile (Q2, 80.10–124.61 µg/day) and the third quintile (Q3, >124.61 µg/day) were 0.80 [95% confidence interval (CI): 0.70–0.92, p = 0.002] and 0.61 (95% CI: 0.51–0.73, p < 0.001), respectively. A negative relationship was observed between dietary selenium intake and sarcopenia (non-linear: p = 0.285). Furthermore, sensitivity analyses revealed a robust association between selenium intake and the prevalence of sarcopenia after further adjusting for blood selenium levels.

Conclusion: The results suggest an inverse association between dietary selenium intake and the prevalence of sarcopenia among American adults.

KEYWORDS

dietary selenium intake, sarcopenia, muscle mass, cross-sectional study, National Health and Nutrition Examination Survey

Introduction

Sarcopenia, a prevalent age-related condition, is characterized by a progressive loss of skeletal muscle mass and function. This decline in muscle physiology leads to diminished physical performance, decreased quality of life, and increased mortality risk (1, 2). The etiology of sarcopenia is multifaceted and not entirely understood, but it is commonly attributed to a combination of factors, including physical inactivity, the aging process, and hormonal imbalances (3). Moreover, nutritional intake plays a crucial role in preserving muscle mass and function throughout life (1).

Selenium, an essential trace element, is vital for normal human body function (4, 5). In mammals, selenium is incorporated into 25 specific selenoproteins

as selenocysteine (Sec) (6). Dietary selenium exists in several forms, including selenomethionine, selenocysteine, selenite, and selenate, all of which are efficiently absorbed and have high bioavailability (7). The recommended dietary allowance for selenium in American adults is 55 μ g per day (8).

Selenium plays a key role in the synthesis of selenoprotein, a complex process that involves the intracellular recycling of selenium, which is facilitated by selenocysteine metabolism through the action of selenocysteine lyase (9). The synthesis of selenoproteins involves incorporating Sec at UGA stop codons, a process mediated by the Selenocysteine Insertion Sequence (SECIS) located in the mRNA's 3' untranslated region and SECIS-binding protein 2 (SBP2) (10). Selenophosphate synthetase converts selenide into monoselenophosphate, which is crucial for synthesizing Sec-tRNA [Ser]Sec, ensuring the accurate incorporation of Sec into the growing polypeptide chain (7).

These selenoproteins function as oxidoreductase enzymes and are involved in various metabolic processes (11), including scavenging of free radicals, maintaining intracellular redox balance, and repairing oxidized lipids and methionines. Research indicates that selenoproteins are vital for their musculoskeletal function and may help mitigate the effects of reactive oxygen species, such as hydrogen peroxide (12, 13).

Plasma selenium is a key biomarker for assessing the human selenium status. Although other biofluids such as hair, toenails, and urine can also be analyzed for selenium, plasma testing is most commonly used due to its diagnostic preference (7). Low serum selenium levels have been associated with worse sarcopenic outcomes (14). While dietary intake is the primary source of selenium, research on the association between dietary selenium consumption and adult sarcopenia is limited. Prolonged parenteral nutrition, which can lead to selenium deficiency, has been linked to symptoms such as muscle pain and weakness, which have been resolved with selenium supplementation (15, 16). We hypothesize an inverse association between dietary selenium intake and sarcopenia. To test this hypothesis, we conducted a cross-sectional study to examine the relationship between dietary selenium intake and sarcopenia in American adults.

Methods

Survey description and study population

This cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES), covering the periods 1999–2006 and 2011–2018, as managed by the Centers for Disease Control and Prevention (CDC). NHANES aims to assess the health and nutritional status of non-institutionalized Americans. Participants were selected using a stratified probability sampling design involving a multistage process (17). The NHANES dataset encompasses various health metrics, including demographic characteristics, physical examination results, laboratory findings, and dietary habits. Data collection was overseen by the National Center for Health Statistics (NCHS) and adhered to rigorous ethical standards, with informed consent obtained from all participants. The dataset is publicly available through the NHANES website (http://www.cdc.gov/nchs/nhanes. htm). This study included individuals aged 20 years and older who completed the survey. Pregnant women and individuals with incomplete data on dual-energy x-ray absorptiometry (DXA), body mass index (BMI), dietary selenium intake, covariates, or sample weights were excluded from the analysis.

Assessment of sarcopenia

DXA is highly regarded for measuring body composition due to its speed, ease of use, and minimal radiation exposure (18, 19). From 1999 to 2006, whole-body DXA scans were performed using the Hologic QDR 4500A fan-beam densitometer (Hologic, Inc., Bedford, Massachusetts, USA). From 2011 to 2018, scans were conducted using the Hologic Discovery model A densitometers (Hologic, Inc., Bedford, Massachusetts, USA) with software version Apex 3.2.

Appendicular skeletal muscle mass (ASM) is a critical metric derived from DXA scans, representing the total lean mass of the extremities, including both arms and legs. This measurement is obtained by summing the lean mass, excluding the bone mineral content, provided by DXA scans for these regions. This study assessed sarcopenia using the sarcopenia index, calculated as ASM adjusted by BMI (ASM/BMI). According to the criteria set by the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project (20), men were classified as having sarcopenia if their sarcopenia index was <0.789 and women were classified as having sarcopenia if their sarcopenia index was <0.512. These criteria have been employed in recent research (21, 22).

Assessment of dietary selenium intake

Dietary intake was assessed over 2 separate days in the NHANES study: the initial session was conducted in person, followed by a subsequent session via telephone. Due to significant data gaps encountered during the second round of interviews, our analysis relied solely on the dietary information collected during the initial session. Estimations of dietary selenium and other nutrients were based on data from the Food and Nutrient Database for Dietary Studies (http://www.ars.usda.gov/ba/bhnrc/fsrg), a comprehensive resource provided by the United States Department of Agriculture (23).

Covariates

A variety of potential covariates were assessed according to the literature (24–32), including age, sex, marital status, race/ethnicity, education level, poverty income ratio (PIR), smoking status, hypertension, diabetes, cardiovascular diseases (CVDs), cancer, physical activity, healthy eating index-2015 (HEI-2015), dietary supplements taken, albumin, estimated glomerular filtration rate (eGFR), uric acid, and total cholesterol. Race/ethnicity was categorized as Non-Hispanic White, Non-Hispanic Black, Mexican



American, or other races (26). Marital status was classified into two groups: those who were either married or living with a partner and those who were living alone (26). The educational level was categorized into three groups: less than high school, high school or equivalent, and above high school (27). Family income was divided into three categories based on the PIR: PIR \leq 1.30, PIR 1.31–3.50, and PIR > 3.50 (27). Smoking status was categorized as never smokers (smoked <100 cigarettes), current smokers, and former smokers (quit smoking after smoking more than 100 cigarettes) (29). Drinking status was self-reported and categorized as never (had <12 drinks in a lifetime), former (had \geq 12 drinks in 1 year and did not drink last year, or did not drink last year but drank \geq 12 drinks in a lifetime), mild (female drinking \leq 1 and male drinking ≤ 2 per day), moderate (female drinking ≤ 2 and male drinking ≤ 3 per day), or heavy (female drinking ≥ 3 and male drinking \geq 4 per day) (27). The definition of hypertension was selfreported diagnosis, use of antihypertensive drugs, systolic blood pressure \geq 140 mmHg, or diastolic blood pressure \geq 90 mmHg (24). The definition of diabetes was self-reported diagnosis, use of insulin or oral hypoglycemic agents, fasting glucose \geq 7 mmol/L, or HbA1c \geq 6.5% (31). The CVD history was self-reported as having previously been diagnosed with heart failure, coronary heart disease, angina, heart attack, or stroke (27). The cancer history was self-reported as having been diagnosed with cancer or malignancy. The Healthy Eating Index (HEI) is a robust metric for evaluating the overall quality of an individual's diet, explicitly gauging the alignment of dietary habits with the established Dietary Guidelines for Americans (30). HEI-2015 scores range from 0 to 100, with higher values signifying better diet quality. The Healthy Eating Index (HEI) comprises 13 components that assess compliance with dietary guidelines, including the consumption of the recommended food groups and the limitation of less healthy options. We calculated the HEI scores based on total nutrient intakes from the initial day of dietary assessment, capturing participants' adherence to HEI-2015 standards, which emphasize aspects such as fruit and vegetable intake, whole grains, and reductions in added sugars and saturated fats (30). Dietary supplements were determined by the question regarding nutritional supplements and medications consumed during the past month (29). Furthermore, we quantified the level of physical activity by employing the metabolic equivalent of task (MET), measured in minutes per week (32). Additionally, the eGFR was determined using the Chronic Kidney Disease

TABLE 1 Baseline characteristics by dietary selenium intake level.

Characteristics	Dietary selenium intake (µg/day)						
	Total	Q1 (<80.10)	Q2 (80.10-124.61)	Q3 (>124.61)			
	n = 19,696	n = 6,559	n = 6,569	n = 6,568			
Age, mean (SD), years	43.54 (14.86)	45.58 (15.92)	43.83 (14.96)	41.42 (13.41)	< 0.001		
Sex, n (%)					< 0.001		
Male	9,830 (49.31)	2,194 (30.95)	3,143 (45.85)	4,493 (69.29)			
Female	9,866 (50.69)	4,365 (69.05)	3,426 (54.15)	2,075 (30.71)			
Race/ethnicity, <i>n</i> (%) ^a					0.001		
Non-Hispanic White	9,167 (69.74)	2,980 (68.94)	3,136 (70.90)	3,051 (69.36)			
Non-Hispanic Black	3,877 (10.24)	1,442 (11.76)	1,252 (9.93)	1,183 (9.17)			
Mexican American	3,715 (8.15)	1,256 (7.47)	1,236 (7.81)	1,223 (9.09)			
Other Hispanic	1,221 (5.36)	393 (5.54)	406 (5.20)	422 (5.36)			
Others ^b	1,716 (6.50)	488 (6.28)	539 (6.17)	689 (7.02)			
Education level, n (%)					< 0.001		
Less than high school	4,700 (14.87)	1,920 (18.68)	1,454 (13.21)	1,326 (12.99)			
High school or equivalent	4,500 (24.02)	1,521 (25.23)	1,512 (24.34)	1,467 (22.62)			
Above high school	10,496 (61.11)	3,118 (56.09)	3,603 (62.45)	3,775 (64.39)			
Marital status, n (%)					0.002		
Married or living with a partner	12,261 (64.05)	3,839 (61.48)	4,140 (64.83)	4,282 (64.39)			
Living alone	7,435 (35.95)	2,720 (38.52)	2,429 (35.17)	2,286 (34.37)			
PIR, <i>n</i> (%)							
≤1.3	5,554 (20.82)	2,118 (24.80)	1,755 (19.65)	1,681 (18.31)			
>1.3-3.5	7,428 (34.97)	2,483 (35.65)	2,522 (35.10)	2,423 (34.24)			
>3.5	6,714 (44.21)	1,958 (39.56)	2,292 (45.25)	2464 (47.45)			
BMI, mean (SD), kg/m ²	28.48 (6.50)	28.30 (6.68)	28.45 (6.41)	28.68 (6.41)	0.062		
Smoking status, n (%)					0.004		
Never	10,766 (53.83)	3,645 (53.59)	3,588 (54.11)	3,533 (53.80)			
Former	4,532 (23.11)	1,424 (21.22)	1,597 (23.96)	1,511 (24.02)			
Now	4,398 (23.05)	1,490 (25.19)	1,384 (21.93)	1,524 (22.19)			
Drinking status, n (%)					< 0.001		
Never	2,606 (11.11)	1,146 (14.67)	828 (10.77)	632 (8.21)			
Former	3,187 (13.48)	1,248 (15.22)	1,089 (13.94)	850 (11.48)			
Mild	6,491 (34.37)	1,955 (31.16)	2,228 (35.93)	2,308 (35.80)			
Moderate	3,177 (18.26)	1,010 (18.15)	1,133 (18.89)	1,034 (17.31)			
Heavy	4,235 (22.77)	1,200 (20.31)	1,291 (20.47)	1,744 (27.20)			
Hypertension, <i>n</i> (%)	7,199 (32.77)	2,653 (35.03)	2,433 (31.86)	2,113 (31.58)	0.005		
Diabetes, n (%)	2,404 (8.93)	870 (9.66)	856 (9.13)	678 (8.08)	0.039		
CVD history, <i>n</i> (%)	1,580 (6.37)	672 (7.77)	530 (6.67)	378 (4.81)	<0.001		
Cancer history, <i>n</i> (%)	1,307 (7.02)	526 (8.28)	472 (7.96)	309 (4.99)	< 0.001		
Physical activity MET, mean (SD), min/week	2,187.82 (4,519.00)	1,783.69 (3,941.14)	2,028.26 (4,227.69)	2,706.68 (5,181.76)	< 0.001		
HEI-2015, mean (SD)	51.92 (13.21)	51.77 (13.64)	52.06 (13.03)	51.92 (12.99)	0.662		
Dietary supplements taken, <i>n</i> (%)	9,524 (52.16)	3,144 (51.98)	3,255 (54.04)	3,125 (50.53)	0.023		

(Continued)

Characteristics		P-value				
	Total	Q1 (<80.10)	Q2 (80.10-124.61)	Q3 (>124.61)		
	n = 19,696	n = 6,559	n = 6,569	n = 6,568		
ALT, mean (SD), U/L	26.33 (25.24)	23.76 (18.30)	25.70 (21.88)	29.27 (32.37)	< 0.001	
AST, mean (SD), U/L	25.27 (17.03)	24.45 (15.83)	25.05 (18.79)	26.22 (16.25)	< 0.001	
Albumin, mean (SD), g/dL	4.33 (0.33)	4.29 (0.33)	4.33 (0.33)	4.38 (0.32)	< 0.001	
Creatinine, mean (SD), mg/dL	0.87 (0.34)	0.85 (0.39)	0.86 (0.34)	0.90 (0.28)	< 0.001	
Uric acid, mean (SD), mg/dL	5.38 (1.40)	5.17 (1.40)	5.32 (1.39)	5.62 (1.36)	< 0.001	
Total cholesterol, mean (SD), mg/dL	198.20 (41.46)	199.94 (42.54)	198.59 (40.60)	196.24 (41.20)	0.002	
eGFR, mean (SD), mL/(min·1.73 m ²)	99.38 (19.38)	97.56 (20.88)	99.46 (19.28)	100.96 (17.85)	< 0.001	
Sarcopenia, n (%)	2,340 (8.46)	987 (10.81)	812 (8.44)	541 (6.35)	< 0.001	

TABLE 1 (Continued)

Q, quartiles; SD, standard deviation; PIR, poverty income ratio; BMI, body mass index; CVD, cardiovascular disease; MET, metabolic equivalent of task; HEI-2015, healthy eating index-2015; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate.

Data are presented as unweighted numbers (weighted percentages) for categorical variables, and all means and SDs for continuous variables were weighted.

^aRace and ethnicity were self-reported.

^b Includes multiracial participants. NHANES does not provide a detailed list of all races and ethnicities. A *p*-value of < 0.05 was set as the threshold of statistical significance.

Epidemiology Collaboration (CKD-EPI) formula, a reliable method for evaluating kidney function.

Statistical analysis

Our analysis accounted for the complex sampling design and dietary sample weights. For the combined NHANES 1999-2000 and 2001-2002 datasets, we used the 4-year dietary weight (WTDR4YR). We applied the dietary day-one sample weight for the datasets from 2003 to 2004, 2005 to 2006, 2011 to 2012, 2013 to 2014, 2015 to 2016, and 2017 to 2018 (WTDRD1). Sampling weights were calculated as follows: for the 1999-2002 period, weights were set at $1/4 \times$ WTDR4YR, and for other years, they were set at $1/8 \times$ WTDRD1. Categorical data are presented as unweighted counts with weighted percentages, while continuous data are reported as means \pm standard deviations (SD). Differences between groups were assessed using one-way analyses of variance for continuous variables and chi-square tests for categorical variables. A multivariate logistic regression analysis was employed to determine the association between dietary selenium intake and sarcopenia, with results expressed as odds ratios (ORs) and 95% confidence intervals (CIs).

Model 1 adjusted for demographic variables, including age, gender, marital status, race/ethnicity, PIR, and education level. Model 2 further accounted for smoking status, alcohol consumption, hypertension, diabetes, CVD history, cancer history, physical activity, HEI-2015, and use of dietary supplements. Model 3 included additional adjustments for albumin, eGFR, uric acid, and total cholesterol.

To evaluate the dose-response relationship between dietary selenium intake and sarcopenia, we employed a restricted cubic spline (RCS) regression model with three knots positioned at the 10th, 50th, and 90th percentiles of dietary selenium intake. This approach allowed us to assess linearity and explore the relationship after adjusting for the covariates in Model 3. We also performed interaction and subgroup analyses using logistic regression models stratified by age, sex, race/ethnicity, marital status, PIR, smoking status, alcohol consumption, hypertension, diabetes, CVD history, cancer history, and eGFR.

Two sensitivity analyses were conducted to ensure the robustness of our results. Initially, the primary analysis did not include serum selenium due to substantial missing serum selenium data and potential collinearity with dietary selenium. To address whether dietary selenium remains associated with sarcopenia after adjusting for serum selenium, we conducted a sensitivity analysis excluding participants without serum selenium data, followed by a multivariate logistic regression analysis that included serum selenium along with the covariates from Model 3. Multiple imputations with five replications were also used to handle missing covariate data.

Although no prior statistical power calculations were conducted, the large sample size of 19,696 participants provided substantial analytical power. To verify this, we subsequently used G*Power software to assess the power of our analyses, which indicated a power of 1. All statistical analyses were performed using R Statistical Software (Version 4.2.2, http://www.R-project.org, The R Foundation) and the Free Statistics analysis platform (Version 1.9.2, Beijing, China, http://www.clinicalscientists.cn/freestatistics). Descriptive statistics were computed for all participants, and statistical significance was evaluated using a two-tailed test with a threshold of p of < 0.05.

Result

Study population

This study utilized data from eight NHANES cycles: 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2011–2012, 2013–2014, 2015–2016, and 2017–2018. A total of 42,928 participants aged 20 years and older completed the survey. We excluded

TABLE 2 Association of covariates and sarcopenia.

Covariates	OR (95% CI)	P-value
Age (years)	1.05 (1.04–1.05)	< 0.001
Sex		
Female (vs. male)	0.86 (0.75–0.97)	0.018
Race/ethnicity (vs. Non-Hi	spanic White)	
Non-Hispanic Black	0.33 (0.26-0.41)	< 0.001
Mexican American	2.89 (2.48-3.37)	< 0.001
Other Hispanic	1.96 (1.56–2.47)	< 0.001
Others	1.19 (0.91–1.54)	0.195
Education level (vs. less that	an high school)	
High school or equivalent	0.58 (0.50-0.67)	< 0.001
Above high school	0.33 (0.28–0.38)	< 0.001
Marital status (vs. married o	or living with a partner)	
Living alone	0.88 (0.77-1.02)	0.084
PIR (vs. ≤1.3)		
>1.3-3.5	0.82 (0.68–0.97)	0.024
>3.5	0.43 (0.37–0.52)	< 0.001
Hypertension (yes vs. no)	2.79 (2.42-3.21)	< 0.001
Diabetes (yes vs. no)	3.82 (3.26-4.48)	< 0.001
CVD history (yes vs. no)	3.66 (3.08-4.35)	< 0.001
Cancer history (yes vs. no)	1.47 (1.15–1.87)	0.002
Smoking status (vs. never)		
Former	1.36 (1.16–1.59)	< 0.001
Now	0.79 (0.68–0.93)	0.006
Drinking status (vs. never)		
Former	1.15 (0.92–1.44)	0.218
Mild	0.5 (0.40-0.63)	< 0.001
Moderate	0.38 (0.29–0.49)	< 0.001
Heavy	0.48 (0.37-0.62)	< 0.001
Physical activity MET, min/week	1 (1.00–1.00)	<0.001
HEI-2015	1 (0.99–1.00)	0.163
Dietary supplements taken (yes vs. no)	0.95 (0.82–1.09)	0.456
ALT, U/L	1 (1.00–1.00)	0.135
AST, U/L	1 (1.00–1.01)	0.156
Albumin, g/dL	0.26 (0.22–0.31)	< 0.001
Creatinine, mg/dL	0.87 (0.66–1.15)	0.324
Uric acid, mg/dL	1.2 (1.15–1.26)	<0.001
Total cholesterol, mg/dL	1 (1.00–1.00)	<0.001
eGFR, mL/(min·1.73 m ²)	0.99 (0.99–0.99)	<0.001
Dietary selenium intake, µg/day	1 (0.99–1.00)	<0.001

(Continued)

TABLE 2 (Continued)

Covariates	OR (95% CI)	P-value					
Dietary selenium intake (vs. Q1 $<$ 80.10 μ g/day)							
Q2 (80.10–124.61 µg/day)	0.76 (0.67–0.87)	< 0.001					
Q3 (>124.61 µg/day)	0.56 (0.48-0.66)	< 0.001					

Q, quartiles; PIR, poverty income ratio; CVD, cardiovascular disease; MET, metabolic equivalent of task; HEI–2015, healthy eating index-2015; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; CI, confidence interval; OR, odds ratio.

The unit for continuous variables and the reference group for categorical variables are provided next to the variables. A p-value of < 0.05 was set as the threshold of statistical significance.

pregnant women (n = 1,421) and participants with missing data on DXA (n = 13,974), BMI (n = 213), and dietary selenium intake (n = 1,340). Participants without data on sample weights (n = 13) and covariates (n = 6,271) were excluded. Consequently, the final sample consisted of 19,696 participants (Figure 1).

Baseline characteristics

The baseline characteristics of the 19,696 participants with available data for analysis are summarized in Table 1. These participants represent ~124.60 million American adults aged 20 years and older. The mean age was 43.54 (14.68) years, with 9,830 (49.31%) being male. The overall prevalence of sarcopenia was 8.46%. Higher dietary selenium intake was generally observed among younger participants, men, those with a PIR of > 3.5, married or cohabiting individuals, mild alcohol consumers, non-smokers, and those with higher educational attainment. Additionally, higher selenium intake was associated with greater physical activity, higher levels of albumin, uric acid, and eGFR, a lower incidence of hypertension, diabetes, CVD, cancer, and lower total cholesterol levels.

Relationship between dietary selenium intake and sarcopenia

The univariable analysis showed that age, sex, race/ethnicity, education level, PIR, smoking status, alcohol consumption, hypertension, diabetes, CVD, cancer, physical activity, albumin, uric acid, total cholesterol, eGFR, and dietary selenium intake were linked to sarcopenia (Table 2).

An inverse association between dietary selenium consumption and sarcopenia was observed after adjusting for potential confounders (Table 3). Compared to the lowest dietary selenium intake quintile (Q1, <80.10 μ g/day), the adjusted ORs for sarcopenia in Q2 (80.10–124.61 μ g/day) and Q3 (>124.61 μ g/day) were 0.80 (95% CI: 0.70–0.92, p = 0.002) and 0.61 (95% CI: 0.51–0.73, p < 0.001),

TABLE 3 Association between dietary selenium intake and sarcopenia.

	Crude		Model 1		Model 2		Model 3	
	OR (95% CI)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value	OR (95% CI)	P-value
Dietary selenium intake								
Q1 (<80.10 µg/day)	1 (Reference)		1 (Reference)		1 (Reference)		1 (Reference)	
Q2 (80.10–124.61 µg/day)	0.76 (0.67–0.87)	< 0.001	0.82 (0.72–0.94)	0.004	0.83 (0.72–0.95)	0.006	0.8 (0.70-0.92)	0.002
Q3 (>124.61 µg/day)	0.56 (0.48–0.66)	< 0.001	0.64 (0.53–0.76)	<0.001	0.64 (0.54–0.77)	<0.001	0.61 (0.51-0.73)	< 0.001
<i>P</i> for trend		< 0.001		< 0.001		< 0.001		< 0.001

Model 1: adjusted for age, sex, poverty income ratio, race/ethnicity, education level, and marital status.

Model 2: adjusted for model 1+ smoking status, alcohol drinking status, hypertension, diabetes, cardiovascular disease history, cancer history, physical activity, healthy eating index-2015, and dietary supplements taken.

Model 3: adjusted for model 2+ albumin, estimated glomerular filtration rate, uric acid, and total cholesterol.

Q, quartiles; CI, confidence interval; OR, odds ratio.

A *p*-value of < 0.05 was set as the threshold of statistical significance.



activity, healthy eating index-2015, dietary supplements taken, albumin, estimated glomerular filtration, uric acid, and total cholesterol.

respectively. Evidence from the estimated dose-response curve indicated a significant linear relationship between dietary selenium intake and sarcopenia (Figure 2, p for non-linearity = 0.285).

Subgroup analyses

In several subgroups, a stratified analysis was conducted to assess potential effect modifications on the relationship

	intake(µg/day)	total,No.	01 (00/001)		2 Ioi interaction	Sundionb	intake(µg/day)	total,No.	01 (03%01)		. Ior meraction
Age,years					0.416	Sex					0.789
<65						Male					
	Q1(<80.10)	563/5195	1(Reference)	+			Q1(<80.10)	393/2194	1(Reference)	+	
	Q2(80.10-124.61)	515/5594	0.79(0.66, 0.95)				Q2(80.10-124.61)	436/3143	0.81(0.67, 0.99)		
	Q3(>124.61)	422/6051	0.64(0.52, 0.79)				Q3(>124.61)	387/4493	0.64(0.50, 0.82)		
265						Female					
	01/280 100	101/1001	1/Deference)				01/-20 10	E04/420E	(Deferment)		
	01(<80.10)	424/1304	(Relefence)				01(<00.10)	004/4000	(Relefence)		
	Q2(80.10-124.61)	297/975	0.87(0.70, 1.09)				Q2(80.10-124.61)	376/3426	0.82(0.67, 1.00)		
	Q3(>124.61)	119/517	0.57(0.40, 0.81)				Q3(>124.61)	154/2075	0.65(0.50, 0.86)		
Race/ethnicity					0.693	Drinking status					0.475
Non-Hispanic White						Never					
	Q1(<80.10)	411/2980	1(Reference)	•			Q1(<80.10)	228/1146	1(Reference)	•	
	Q2(80.10-124.61)	335/3136	0.75(0.62, 0.89)				Q2(80.10-124.61)	146/828	0.92(0.63, 1.35)		_
	Q3(>124.61)	206/3051	0.60(0.46, 0.79)				03(>124.61)	72/632	0.63(0.38, 1.03)		
Non-Hispania Disek						Formar					
Non-Hispanic black		-				Former					
	Q1(<80.10)	57/1442	1(Reference)				Q1(<80.10)	285/1248	1(Reference)	•	
	Q2(80.10-124.61)	42/1252	0.67(0.34, 1.30)		-		Q2(80.10-124.61)	220/1089	0.84(0.61, 1.15)		
	Q3(>124.61)	19/1183	0.35(0.16, 0.79)				Q3(>124.61)	97/850	0.56(0.38, 0.81)		
Mexican American						Mild					
	Q1(<80.10)	396/1256	1(Reference)	+			Q1(<80.10)	240/1955	1(Reference)	•	
	Q2(80.10-124.61)	327/1236	0.94(0.70, 1.25)		-		Q2(80.10-124.61)	229/2228	0.89(0.68, 1.17)	_	
	Q3(>124.61)	221/1223	0.66(0.49. 0.89)				Q3(>124.61)	183/2308	0.82(0.60. 1.12)		
Others Missessia	20(- 10-101)		0.0010.00, 0.001			Madauati	20(- 12-101)		0.00(0.00, 1.16)		
Ourier Hispanic	5.511 (1.500 (·····					moderate					
	Q1(<80.10)	69/393	1(Reference)	+			Q1(<80.10)	101/1010	1(Reference)	+	
	Q2(80.10-124.61)	62/406	1.16(0.69, 1.94)				Q2(80.10-124.61)	81/1133	0.58(0.35, 0.96)		
	Q3(>124.61)	53/422	0.86(0.51, 1.44)		_		Q3(>124.61)	52/1034	0.40(0.25, 0.65)		
Others						Heavy					
	Q1(<80.10)	54/488	1(Reference)				Q1(<80.10)	133/1200	1(Reference)		
	02(80 10-124 61)	46/520	0.00/0.49, 1.69)		_		02(80 10-124 61)	126/1201	0.83/0.54 1.27)		_
	02(00.10-124.01)	40/000	0.30(0.40, 1.03)				02(00.10-124.01)	1001201	0.05(0.04, 1.27)		
	Q3(>124.61)	42/689	0.75(0.40, 1.45)				Q3(>124.61)	137/1744	0.64(0.42, 0.97)	-	
Marital status					0.477	Smoking status					0.71
Married or living with a partner						Never					
	Q1(<80.10)	622/3839	1(Reference)	+			Q1(<80.10)	537/3645	1(Reference)	+	
	Q2(80.10-124.61)	538/4140	0.82(0.69, 0.98)				Q2(80.10-124.61)	414/3588	0.85(0.68, 1.06)		
	Q3(>124.61)	386/4282	0.64(0.50, 0.80)				Q3(>124.61)	293/3533	0.70(0.52, 0.94)		
Living alone						Former					
	01/-90 100	265/2720	1/Beferenze)				01/-20 10	202/1424	1/Pelerenes)		
	41(-00:10)	00012120	((relatence)				41(100.10)	2001424	(((((((((((((((((((((((((((((((((((((((
	Q2(80.10-124.61)	274/2429	0.81(0.62, 1.06)	_			Q2(80.10-124.61)	276/1597	0.77(0.58, 1.03)		
	Q3(>124.61)	155/2286	0.64(0.46, 0.89)				Q3(>124.61)	153/1511	0.59(0.42, 0.82)		
PIR					0.289	Now					
s1.3							Q1(<80.10)	158/1490	1(Reference)	•	
	Q1(<80.10)	414/2118	1(Reference)	+			Q2(80.10-124.61)	122/1384	0.77(0.56, 1.05)		
	Q2(80.10-124.61)	288/1755	0.86(0.69, 1.09)				Q3(>124.61)	95/1524	0.56(0.39, 0.80)		
	Q3(>124.61)	186/1681	0.61(0.46, 0.81)			Hypertension					0.864
12-2 E						No					
-1.3-3.5						NO					
	Q1(<80.10)	376/2483	1(Reference)	•			Q1(<80.10)	407/3905	1(Reference)	•	
		367/2522	0.91(0.73, 1.13)				Q2(80.10-124.61)	354/4136	0.89(0.71, 1.12)		
	Q2(80.10-124.61)						000 101 011	274/4455			
	Q2(80.10-124.61) Q3(>124.61)	216/2423	0.66(0.50, 0.89)				Q3(>124.01)		0.68(0.52, 0.89)		
>3.5	Q2(80.10-124.61) Q3(>124.61)	216/2423	0.66(0.50, 0.89)	-•		Yes	Q3(>124.61)		0.68(0.52, 0.89)		
>3.5	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10)	216/2423 197/1958	0.68(0.50, 0.89) 1(Reference)	-		Yes	Q3(>124.61) Q1(<80.10)	580/2653	0.68(0.52, 0.89) 1(Reference)		
>3.5	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61)	216/2423 197/1958 157/2292	0.66(0.50, 0.89) 1(Reference) 0.66(0.49, 0.88)	_+_ 		Yes	Q3(>124.61) Q1(<80.10) Q2(80.10-124.61)	580/2653	0.68(0.52, 0.89) 1(Reference) 0.77(0.62, 0.95)	_	
>3.5	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	218/2423 197/1958 157/2292	0.66(0.50, 0.89) 1(Reference) 0.66(0.49, 0.86)	 		Yes	Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	580/2653 458/2433	0.68(0.52, 0.89) 1(Reference) 0.77(0.62, 0.95)	-+	
>3.5	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	216/2423 197/1958 157/2292 139/2484	0.68(0.50, 0.89) 1(Reference) 0.66(0.49, 0.88) 0.60(0.41, 0.89)	+		Yes	Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	580/2653 458/2433 267/2113	0.68(0.52, 0.89) 1(Reference) 0.77(0.62, 0.95) 0.57(0.44, 0.74)		
>3.5 CVD history	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	216/2423 197/1958 157/2292 139/2464	0.68(0.50, 0.89) 1(Reference) 0.66(0.49, 0.88) 0.60(0.41, 0.89)	+ + +	0.625	Yes Diabetes	Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	580/2653 458/2433 267/2113	0.68(0.52, 0.89) 1(Reference) 0.77(0.62, 0.95) 0.57(0.44, 0.74)		0.349
>3.5 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	218/2423 197/1958 157/2292 139/2464	0.68(0.50, 0.89) 1(Reference) 0.68(0.49, 0.88) 0.69(0.41, 0.89)	+ + +	0.625	Yes Diabetes No	Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	580/2653 458/2433 267/2113	0.68(0.52, 0.89) 1(Reference) 0.77(0.62, 0.95) 0.57(0.44, 0.74)	+	0.349
>3.5 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10)	216/2423 197/1958 157/2292 139/2464 798/5887	0.68(0.50, 0.89) 1(Reference) 0.68(0.49, 0.88) 0.60(0.41, 0.89) 1(Reference)	+ + +	0.625	Yes Diabetes No	Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10)	580/2653 458/2433 267/2113 753/5689	0.68(0.52, 0.89) 1(Reference) 0.77(0.62, 0.95) 0.57(0.44, 0.74) 1(Reference)	_+ _+	0.349
>35 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61)	216/2423 197/1958 157/2292 139/2464 798/5887 665/6039	0.88(0.50, 0.89) 1(Reference) 0.68(0.49, 0.88) 0.60(0.41, 0.89) 1(Reference) 0.79(0.67, 0.92)	+ + + +	0.625	Yes Diabetes No	Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61)	580/2653 458/2433 267/2113 753/5689 585/5713	0 68(0.52, 0.89) 1(Reference) 0 77(0.62, 0.89) 0 57(0.44, 0.74) 1(Reference) 0 78(0.56, 0.91)	-+ -+	0.349
>35 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61)	216/2423 197/1958 157/2292 139/2464 798/5887 665/6039 467/6190	0.88(0.50, 0.89) 1(Reterence) 0.88(0.48, 0.88) 0.80(0.41, 0.89) 1(Reterence) 0.78(0.67, 0.82) 0.80(0.49, 0.74)	+++++++++++++++++++++++++++++++++++++++	0.625	Yes Diabetes No	C3(~124.61) C1(~80.10) C2(80.10-124.61) C3(>124.61) C1(~80.10) C2(80.10-124.61) C3(>124.61) C3(>124.61)	580/2653 458/2433 267/2113 753/5689 585/5713 403/5890	0.68(0.52, 0.89) 1(Reference) 0.77(0.82, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.78(0.86, 0.91) 0.61(0.44, 0.75)		0.349
>35 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q2(>124.61) Q3(>124.61)	216/2423 197/1958 157/2392 139/2464 798/5887 665/8039 467/6190	0.68(0.56, 0.89) 1(Reference) 0.68(0.48, 0.88) 0.60(0.41, 0.89) 1(Reference) 0.79(0.67, 0.92) 0.60(0.40, 0.74)	+ + + + +	0.625	Yes Diabetes No	C3(~124.61) C1(~80.10) C2(80.10-124.61) C3(~124.61) C1(~80.10) C2(80.10-124.61) C3(~124.61)	580/2653 458/2433 267/2113 753/5689 585/5713 403/5890	0 680(52, 0 89) 1(Reference) 0 77(0 82, 0 95) 0 57(0 44, 0 74) 1(Reference) 0 78(0 86, 0 91) 0 681(0 49, 0 75)	+ + +	0.349
>35 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q1(<80.10) Q	218/2423 197/1958 157/2292 139/2464 799/5987 665/6039 467/6190	0.66(0.50, 0.69) 1((Reference) 0.66(0.49, 0.88) 0.66(0.41, 0.89) 1((Reference) 0.79(0.67, 0.92) 0.66(0.40, 0.74)	+++++	0.825	Yes Diabetes No	C3(<24.61) C1(<80.10) C2(80.10-124.61) C3(<24.61) C1(<80.10) C2(80.10-124.61) C3(<24.61) C3(<24.61) C1(<80.10) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24.61) C3(<24	580/2653 458/2433 267/2113 753/5689 585/5713 403/5890 234/870	0 68(0.52, 0.69) 1(Reference) 0.77(0.62, 0.56) 0.57(0.44, 0.74) 1(Reference) 0.78(0.66, 0.91) 0.61(0.46, 0.75) 1(Reference)	+++++	0.349
>35 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(<80.10)	218/2423 197/1958 157/2292 138/2464 798/5887 665/6039 467/5190	0.68(0.50, 0.89) 1(Reference) 0.68(0.48, 0.88) 0.60(0.41, 0.89) 1(Reference) 0.79(0.67, 0.92) 0.60(0.40, 0.74) 1(Reference)	+ + + + +	0.625	Yes Diabetes No	C3(+124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q3(>124.61)	580/2653 458/2433 267/2113 753/5689 585/5713 403/5890 234/870	0 68(0.52, 0.69) 1(Reference) 0.77(0.62, 0.65) 0.57(0.44, 0.74) 1(Reference) 0.78(0.66, 0.91) 0.61(0.49, 0.75) 1(Reference)	+ + + +	0.349
>35 CVD history No	Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q2(80.10-124.61) Q2(80.10-124.61) Q3(>124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61)	218/2423 197/1958 157/2282 139/2464 798/5887 665/8039 467/8190 188/872 147/530	0.66(0.56, 0.89) 1((Reterence) 0.66(0.48, 0.88) 0.66(0.41, 0.89) 1((Reterence) 0.79(0.67, 0.92) 0.60(0.48, 0.74) 1((Reterence) 0.63(0.65, 1.31)	+ + + + +	0.625	Yes Diabetes No Yes	C3(+124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61) Q3(>124.61) Q3(>124.61) Q1(<80.10) Q2(80.10-124.61)	580/2653 458/2433 267/2113 753/5689 585/5713 403/5890 234/870 227/856	0 68(0.52, 0.89) 1(Reference) 0 77(0.52, 0.95) 0 57(0.44, 0.74) 1(Reference) 0 68(0.48, 0.75) 1(Reference) 0 88(0.74, 1.31)	+ + + + +	0.349
>35 CVD history No	C2(80, 10-124.61) C3(0-124.61) C1(-60, 10) C2(80, 10-124.61) C3(0-124.61) C3(0-124.61) C3(0-124.61) C3(0-124.61) C3(0-124.61) C3(0-124.61) C3(0-124.61) C3(0-124.61)	2162423 19771958 15772292 139:2464 798:5987 665:6039 467/6190 189:072 147/530 74/378	0.66(0.56, 0.89) 1((Reference) 0.66(0.48, 0.88) 0.66(0.41, 0.89) 1((Reference) 0.79(0.67, 0.82) 0.60(0.40, 0.74) 1((Reference) 0.59(0.68, 1.31) 0.68(0.40, 1.15)	+ + + + +	0.625	Ves Diabetes No	C3(+124 61) C1(+80,10) C2(80,10-124,61) C3(+124,61) C	580/2653 465/2433 267/2113 753/5689 585/5713 403/5890 234/670 227/856 138/678	0.68(0.52, 0.89) 1(Reference) 0.77(0.52, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.78(0.56, 0.91) 0.61(0.46, 0.75) 1(Reference) 0.68(0.74, 1.31) 0.68(0.74, 1.31)	+ + + + + + + + + + + + + + + + + + + +	0.349
>35 CVD history No Yes Cancer history	Calleo 10-124.61) Calleo 10-124.61) Calleo 100 Calleo 1	218/2423 197/1988 197/2292 139/2494 798/5887 665/6039 467/6190 198/672 147/530 74/378	0.65(0.50, 0.89) 1(Reference) 0.65(0.46, 0.89) 0.65(0.41, 0.89) 1(Reference) 0.75(0.67, 0.92) 0.60(0.41, 0.74) 1(Reference) 0.53(0.65, 1.31) 0.68(0.40, 1.15)	+++++++++++++++++++++++++++++++++++++++	0.625	Yes Diabetes No Yes	C1(<02,10) C1(<02,10) C2(02,10-124,61) C2(02,10-124,61) C2(02,10-124,61) C2(02,10-124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61) C3(<124,61)	580/2653 468/2433 267/2113 753/5689 585/5713 403/5890 234/670 227/856 138/678	0.68(0.52, 0.69) 1(Reference) 0.77(0.62, 0.55) 0.57(0.44, 0.74) 1(Reference) 0.76(0.86, 0.91) 0.81(0.49, 0.75) 1(Reference) 0.98(0.74, 1.31) 0.68(0.47, 1.00)	+ + + + + + + + + + + + + + + + + + +	0.349
>35 CVD history No Yes Cancer history No	Q2(20, 10-124, 81) Q3(-124, 81) Q1(-40, 10) Q2(20, 10-124, 81) Q3(-124, 81) Q3(-124, 81) Q3(-124, 81) Q3(-124, 81) Q3(-124, 81) Q3(-124, 81)	216/2423 197/1958 157/2292 139/2464 799/5987 665/6039 467/6190 189/672 147/530 74/378	0.66(0.56, 0.89) 1((Reterence) 0.66(0.48, 0.88) 0.60(0.41, 0.89) 1((Reterence) 0.79(0.67, 0.92) 0.60(0.48, 0.74) 1((Reterence) 0.39(0.68, 1.31) 0.68(0.40, 1.15)		0.625	Ves Diabetes No Ves eGFR <00	C1(-02.10) C2(02.10-124.61) C2(02.10-124.61) C1(-02.10) C2(02.10-124.61) C3(-124.61) C3(-124.61) C1(-02.10) C2(02.10-124.61) C2(02.10-124.61) C3(-124.61)	5802853 458/2433 267/2113 753/5689 585/5713 403/5890 234/670 227/856 138/678	0 68(0.52, 0.89) 1(Reference) 0.77(0.82, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.78(0.86, 0.91) 0.61(0.49, 0.75) 1(Reference) 0.98(0.74, 1.31) 0.89(0.47, 1.00)	* + + + + + + + + + +	0.349 - 0.897
>35 CVD history No Vite: Cancer history No	C2(20, 10-124, 61) C3(2-124, 61) C1(-46, 10) C2(26, 10-124, 61) C3(2-124, 61) C1(-46, 10) C2(26, 10-124, 61) C1(-46, 10) C2(26, 10-124, 61) C3(2-124, 61) C1(-46, 10) C1(-46, 10)	216/2423 197/1958 157/2292 139/2464 798/5887 665/039 467/6190 189/672 147/530 74/378 891/0033	0.66(0.56, 0.69) 1((Reference) 0.66(0.48, 0.65) 0.66(0.41, 0.69) 1((Reference) 0.76(0.67, 0.62) 0.60(0.48, 0.74) 1((Reference) 0.53(0.65, 1.31) 0.68(0.40, 1.15) 1((Reference)	+++++++++++++++++++++++++++++++++++++++	0.625	Ves Diabetes No Ves eGFR <50	Cale 124 61) Cale 400.10) Cale 400.10) Cale 10-124.61) Cale 400.10) Cale 400.10) Cale 400.10) Cale 400.10) Cale 400.10) Cale 400.10) Cale 400.10) Cale 400.10) Cale 400.10) Cale 400.10)	580/2653 458/2433 267/2113 753/5689 585/5713 403/5890 234/670 227/856 138/678 138/678	0.68(0.52, 0.89) 1(Reference) 0.77(0.52, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.78(0.56, 0.91) 0.61(0.46, 0.75) 1(Reference) 0.68(0.74, 1.31) 0.68(0.74, 1.00)	* + + + + + +	0.349
×35 CVD history No Yes Gancer history No	Calleo, 10-124, 61) Calleo, 10-124, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61	218/2423 197/1988 157/2292 139/2494 798/5887 665/6039 467/6190 188/672 147/530 74/378 891/6033 2286097	0.65(0.50, 0.89) 1(Reference) 0.65(0.46, 0.88) 0.65(0.41, 0.89) 1(Reference) 0.59(0.67, 0.92) 0.69(0.40, 0.74) 1(Reference) 0.69(0.40, 1.15) 1(Reference) 0.69(0.40, 0.74)	+ + + + + + +	0.625	Yes Diabetes No Yes eGFR <80	Cale 124 61) Cale 40. 10) Cale 80. 10-124. 61) Cale 124. 61) Cale 40. 10) Cale 40. 10) Cale 30. 10-124. 61) Cale 30. 10-124. 61)	580/2653 458/2433 267/2113 753/5689 585/5713 403/5890 234/870 227/856 138/678 123/476 67/0/4	0 68(0.52, 0.89) 1(Reference) 0.77(0.82, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.70(0.86, 0.91) 0.61(0.48, 0.75) 1(Reference) 0.58(0.74, 1.31) 0.68(0.74, 1.00) 1(Reference) 0.28(0.47, 1.00)	+ + + + +	0.349
>35 CVD history No Yes Cancer history No	Q2(20,10-124,81) Q3(-124,81) Q1(-40,10) Q2(20,10-124,81) Q3(-124,8	2162423 197/1958 157/2292 139/2464 798/5897 665/6039 467/6190 189/672 147/530 74/378 891/6033 7280603	0.65(0.50, 0.89) 1((Reference) 0.65(0.48, 0.85) 0.60(0.41, 0.89) 1((Reference) 0.79(0.67, 0.92) 0.60(0.46, 0.74) 1((Reference) 0.33(0.65, 1.31) 0.68(0.40, 1.15) 1((Reference) 0.48(0.60, 0.89)	+++++++++++++++++++++++++++++++++++++++	0.625	Ves Diabetes No Yes eGFR <80	Cale 124 61) Cale 426 109 Cale 426 109 Ca	5802653 45802653 28772113 7535689 5855713 4035890 2234670 227856 138678 123476 6773045	0 68(0.52, 0.89) 1(Reference) 0.77(0.52, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.78(0.56, 0.91) 0.61(0.49, 0.75) 1(Reference) 0.98(0.47, 1.31) 0.98(0.47, 1.00) 1(Reference) 0.98(0.42, 1.12) 0.68(0.42, 1.12)	+ + + + + + + + + + +	0.349
>35 CVD history No Yes: Cancer history No	C2(20, 10-124, 61) C2(20, 10-124, 61) C1(460, 10) C2(20, 10-124, 61) C2(20, 10-124, 61)	216/2423 197/1958 157/2292 139/2464 708/6887 e65/6039 467/6190 189/672 147/530 74/378 891/6033 728/6097 507/6299	0.66(0.56, 0.89) 1((Reference) 0.66(0.49, 0.85) 0.66(0.41, 0.89) 1((Reference) 0.79(0.67, 0.92) 0.60(0.40, 0.74) 1((Reference) 0.63(0.65, 1.31) 0.68(0.40, 1.15) 1((Reference) 0.53(0.66, 0.93) 0.61(0.50, 0.74)	+ + + + + + + + + + + + + + + + + + +	0.625	Ves Diabetes No Ves eGFR <60	Contraction (Contraction) Contraction (Contract	5802853 4682433 26772113 7535689 685/5713 4039890 224/870 227/856 138/678 123/476 67/304 20/155	0.68(0.52, 0.89) 1(Reference) 0.77(0.52, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.73(0.56, 0.91) 0.61(0.48, 0.75) 1(Reference) 0.68(0.47, 1.31) 0.69(0.47, 1.00) 1(Reference) 0.68(0.42, 1.12) 0.68(0.42, 1.12)	+ + + + +	0.349
>35 CVD history No Yes Cancer history No	Calleo, 10-124, 61) Calleo, 10-124, 61)	216/2423 197/1988 157/2292 139/2444 798/5887 665/6039 467/8190 189/672 147/530 74/378 89140033 728/0097 507/6299	0.65(0.50, 0.89) 1(Reference) 0.65(0.46, 0.88) 0.65(0.41, 0.89) 1(Reference) 0.79(0.67, 0.82) 0.63(0.63, 0.31) 1(Reference) 0.85(0.40, 1.15) 1(Reference) 0.80(0.60, 0.93) 0.81(0.50, 0.74)	+++++++++++++++++++++++++++++++++++++++	0.625	Ves Diabetes No Ves eGFR <02	Cale 124 61) Cale 40. 10) Cale 50. 10-124. 61) Cale 124. 61) Cale 40. 10) Cale 30. 10-124. 61) Cale 30. 10-124. 61)	5802653 4582433 2672113 7535689 58515713 4035890 234/670 227856 138/678 123476 67/304 20/155	0 68(0.52, 0.89) 1(Reference) 0.77(0.82, 0.16) 0.57(0.44, 0.74) 1(Reference) 0.78(0.86, 0.91) 0.61(0.48, 0.75) 1(Reference) 0.88(0.47, 1.12) 0.68(0.47, 1.12) 0.68(0.42, 1.12) 0.43(0.21, 0.89)	+ + + + + + + + + + + + + + + + + + +	0.349 - 0.897
>35 CVD history No Cancer history No	Q2(20, 10-124, 81) Q3(-124, 81)	216/2423 197/1958 157/2292 139/2464 796/5897 665/6039 467/6190 189/672 147/530 74/378 891/6033 726/6037 507/6259	0.65(0.50, 0.89) 1((Reference) 0.65(0.48, 0.88) 0.65(0.48, 0.89) 1((Reference) 0.79(0.67, 0.92) 0.60(0.49, 0.74) 1((Reference) 0.63(0.40, 1.15) 1((Reference) 0.60(0.69, 0.83) 0.61(0.50, 0.74) 1((Reference))	+ + + + + + +	0.625	Ves Diabetes No Yes eGFR <50	Cale12481) Cale40.10) Cale0.10-124.61) Cale0.10-124.61) Cale124.61) Cale124.61) Cale124.61) Cale124.61) Cale124.61) Cale124.61) Cale124.61) Cale124.61) Cale124.61)	5802653 4582433 267/2113 753/5699 885/5713 403/5890 223/670 227/650 138/678 123/476 67/204 20/155 864/6083	0.68(0.52, 0.89) 1(Reference) 0.77(0.82, 0.95) 0.57(0.44, 0.74) 1(Reference) 0.78(0.86, 0.91) 0.81(0.49, 0.75) 1(Reference) 0.68(0.47, 1.00) 1(Reference) 0.68(0.42, 1.12) 0.43(0.21, 0.68) 1(Reference)	· + + + + + + · + + · · + · · · · · · ·	0.349
>35 CVD history No Cancer history No	Call(20, 10-12.4, 61) Call(20, 10-12.4, 61) Call(40, 10)	2162423 197/1998 157/2292 139/2464 798/5887 665/6039 467/6190 169/672 147/530 74/378 891/6033 728/6097 507/6299 96/528 84/472	0.66(0.50, 0.89) 1((Reterence) 0.66(0.40, 0.85) 0.66(0.40, 0.85) 1((Reterence) 0.79(0.67, 0.92) 0.60(0.40, 0.74) 1((Reterence) 0.63(0.65, 1.31) 0.68(0.40, 1.15) 1((Reterence) 0.63(0.60, 0.93) 0.61(0.50, 0.74) 1((Reterence) 0.65(0.50, 0.74)	↓	0.625	Ves Diabetes No Ves eGFR <60	Cale 124 61) Cale 400.10) Cale 400.10 Cale 400.10 Ca	580/2853 468/2433 267/2113 753/5689 685/5713 403/5890 224/870 227/856 138/878 1234/70 67/304 20155 864/6083 745/8285	0.68(0.52, 0.89) 1(Reference) 0.77(0.52, 0.86) 0.57(0.44, 0.74) 1(Reference) 0.75(0.56, 0.91) 0.61(0.48, 0.75) 1(Reference) 0.68(0.74, 1.31) 0.68(0.47, 1.00) 1(Reference) 0.68(0.42, 1.12) 0.43(0.21, 0.89) 1(Reference) 0.68(0.42, 0.75)	+ + + + + + + + + + + + + + + + + + + +	0.349

FIGURE 3

The relation between dietary selenium intake and sarcopenia according to basic features. Except for the stratification component itself, each stratification factor was adjusted for other variables (age, sex, poverty income ratio, race/ethnicity, education level, marital status, smoking status, alcohol drinking status, hypertension, diabetes, cardiovascular disease history, cancer history, physical activity, healthy eating index-2015, dietary supplements taken, albumin, estimated glomerular filtration, uric acid, and total cholesterol).

TABLE 4 Sensitivity analyses 1.

Dietary selenium intake (µg/day)	Unweighted events/ total, No.	Crude		Adjusted ^b		
		OR (95% CI)	P-value	OR (95% CI)	P-value	
Total ^a	649/4,284					
Q1 (<80.10)	273/1,482	1 (Reference)		1 (Reference)		
Q2 (80.10-124.61)	244/1,470	0.92 (0.76-1.11)	0.378	0.87 (0.70-1.09)	0.219	
Q3 (>124.61)	132/1,332	0.55 (0.38-0.79)	0.002	0.65 (0.43-0.97)	0.036	
<i>P</i> for trend			0.001		0.031	

^aExcluding participants with unavailable serum selenium data.

^bAdjusted for age, sex, poverty income ratio, race/ethnicity, education level, marital status, smoking status, alcohol drinking status, hypertension, diabetes, cardiovascular disease history, cancer history, physical activity, healthy eating index-2015, dietary supplements taken, albumin, estimated glomerular filtration, uric acid, total cholesterol, and serum selenium. Q, quartiles; CI, confidence interval; OR, odds ratio. A *p*-value of < 0.05 was set as the threshold of statistical significance.

TABLE 5 Sensitivity analyses 2.

Dietary selenium intake (µg/day)	Unweighted events/ total, No.	Crude		Adjusted ^b		
		OR (95% CI)	P-value	OR (95% CI)	P-value	
Total ^a	3,100/25,967					
Q1 (<80.10)	1,346/8,842	1 (Reference)		1 (Reference)		
Q2 (80.10–124.61)	1,038/8,509	0.75 (0.66-0.86)	< 0.001	0.77 (0.68–0.89)	< 0.001	
Q3 (>124.61)	716/8,616	0.58 (0.49-0.68)	< 0.001	0.61 (0.51-0.73)	< 0.001	
<i>P</i> for trend			< 0.001		< 0.001	

^aMultiple imputations of missing data.

^bAdjusted for age, sex, poverty income ratio, race/ethnicity, education level, marital status, smoking status, alcohol drinking status, hypertension, diabetes, cardiovascular disease history, cancer history, physical activity, healthy eating index-2015, dietary supplements taken, albumin, estimated glomerular filtration, uric acid, and total cholesterol.

Q, quartiles; CI, confidence interval; OR, odds ratio. A p-value of < 0.05 was set as the threshold of statistical significance.

between dietary selenium intake and sarcopenia. Consistent results were observed when the analysis was stratified by age, sex, race/ethnicity, marital status, PIR, smoking status, alcohol consumption, hypertension, diabetes, CVD, cancer, and eGFR (Figure 3).

Sensitivity analysis

Initially, participants without serum selenium data were excluded. After further adjusting for serum selenium, the adjusted OR for dietary selenium intake and sarcopenia in Q3 (>124.61 μ g/day) was 0.65 (95% CI: 0.43–0.97, p = 0.031) compared to the lowest quintile (Q1: <80.10 μ g/day; Table 4). Multiple imputations with five replications were also conducted to address missing covariate data. Out of the 25,980 participants, sample weight data were not available for 13 of them. Multiple imputations were performed for the remaining 25,967 participants. Compared to the lowest quintile (Q1: <80.10 μ g/day), the adjusted OR for dietary selenium intake and sarcopenia in Q3 (>124.61 μ g/day) was 0.61 (95% CI: 0.51–0.73, p < 0.001; Table 5).

Discussion

This cross-sectional study identified an inverse relationship between dietary selenium intake and sarcopenia. Stratified and

sensitivity analyses further confirmed a robust association between dietary selenium and sarcopenia in American adults. Extensive research suggests that selenium may play a role in musculoskeletal health, with recent studies linking reduced serum selenium levels to exacerbated sarcopenic symptoms (33-37). Despite this finding, evidence regarding the relationship between dietary selenium intake and sarcopenia remains limited and inconsistent. For example, the Newcastle 85+ Study (28) found that low selenium intake was associated with diminished musculoskeletal function in participants aged 85 years and older. Conversely, other studies did not observe a significant relationship between dietary selenium and musculoskeletal health (38-41). Our study contributes to understanding this relationship by demonstrating an inverse association between dietary selenium intake and sarcopenia in American adults, highlighting the need for further prospective research to clarify the effects of selenium on sarcopenia.

According to the dietary reference intakes established by the Institute of Medicine, the recommended daily allowance for selenium in adults is 55 μ g (8). Selenium is sourced from various dietary items, including meats, seafood, cereals, grains, dairy products, fruits, and vegetables. Our study population, consisting of individuals aged 20 years and older, generally exceeds this recommended intake. Therefore, the current recommendation for selenium intake might be insufficient. Some research suggests that the existing recommended daily intake may not be adequate (42). However, excessive selenium intake can lead to toxicity (43), although the World Health Organization considers up to 400 μ g per day to be safe (44). Thus, further research is needed to determine the optimal daily selenium intake.

Selenium is well-regarded for its role in enhancing muscle function, particularly due to its antioxidant properties. Selenoproteins, such as glutathione peroxidase (GPx), are crucial for neutralizing reactive oxygen and nitrogen species, which support muscle health (45–48). These antioxidants are essential for countering oxidative stress, which typically increases with age due to diminished antioxidant defenses (49, 50). The high oxygen demand of skeletal muscle results in the substantial production of reactive nitrogen species, which are associated with reduced muscle strength and mass, often due to increased protein breakdown and decreased muscle protein synthesis (51).

In addition to its antioxidant functions, selenium affects muscle function through other mechanisms. Research indicates that selenium can enhance mitochondrial biogenesis and improve mitochondrial function in skeletal muscle. This effect is partly due to its involvement with various selenoproteins beyond GPx. For instance, selenoprotein H promotes mitochondrial biogenesis, while selenoproteins N and W influence calcium homeostasis in muscles, impacting mitochondrial function (52– 54). Additionally, the presence of selenoprotein O in mitochondria suggests that it may facilitate selenium's redox functions within these organelles (55).

The relationship between selenium and muscle function involves complex regulatory mechanisms, including mitochondrial energetics and cellular signaling pathways (56). Given these diverse roles, selenium is crucial for maintaining muscle function and mitigating age-related declines often linked to oxidative damage and impaired mitochondrial performance. Future longitudinal studies are needed to elucidate the causal mechanisms underlying selenium's effects on muscle function.

The strength of our study lies in its use of a sophisticated multistage probability sampling design combined with rigorous covariate adjustment, which enhances the reliability and representativeness of the findings. Nonetheless, several limitations should be noted. First, the study was conducted exclusively with American adults aged 20 years and older, which may limit the generalizability of the results to other demographic groups. Second, the accuracy and validity of the nutritional assessments were constrained using the 24-h dietary recall method. While food frequency questionnaires were not used due to their provision of less detailed information on specific foods and quantities consumed, their inclusion might have provided additional context (57, 58). Finally, the cross-sectional design of the study prevents concluding causality. Future research using prospective cohort studies is essential to elucidate the cause-and-effect relationship between dietary selenium intake and sarcopenia.

Conclusion

This study identified an inverse relationship between dietary selenium intake and sarcopenia in the adult American population, suggesting that selenium may be a crucial nutrient in influencing the risk of sarcopenia. Based on these findings, we recommend that public health nutritional guidelines incorporate recommendations for adequate selenium intake as a potential strategy to mitigate the risk of sarcopenia. Further longitudinal and interventional studies are essential to establish a causal relationship between selenium intake and sarcopenia and to elucidate the underlying mechanisms. Additionally, research is needed to determine the optimal daily selenium intake for maximizing health benefits.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found at: https://www.cdc.gov/nchs/nhanes.

Ethics statement

The studies involving humans were approved by the National Center for Health Statistics Research Ethics Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

JL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing – original draft, Writing – review & editing. CJ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Writing – review & editing. LW: Data curation, Formal analysis, Methodology, Software, Writing – review & editing. JT: Data curation, Software, Writing – review & editing. BZ: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was financially supported by the Youth Project of Guangdong Provincial Medical Research Fund (Grant No. B2021353), Outstanding Youth Fund Projects of Jiangmen Central Hospital (Grant Nos. J202101 and J202003), and the projects of Jiangmen City Science and Technology Plans (Grant No. 2021YLA01033).

Acknowledgments

We thank Huanxian Liu from the Department of Neurology and Jie Liu from the Department of Vascular and Endovascular Surgery at the Chinese PLA General Hospital for their invaluable support. Their expertise in statistical analysis and study design consultation has contributed to the accomplishment of our research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Bloom I, Shand C, Cooper C, Robinson S, Baird J. Diet quality and sarcopenia in older adults: a systematic review. *Nutrients*. (2018) 10:308. doi: 10.3390/nu10030308

2. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. (2019) 393:2636–46. doi: 10.1016/S0140-6736(19)31138-9

3. Bao W, Sun Y, Zhang T, Zou L, Wu X, Wang D, et al. Exercise programs for muscle mass, muscle strength and physical performance in older adults with sarcopenia: a systematic review and meta-analysis. *Aging Dis.* (2020) 11:863–73. doi: 10.14336/AD.2019.1012

4. Chariot P, Bignani O. Skeletal muscle disorders associated with selenium deficiency in humans. *Muscle Nerve*. (2003) 27:662-8. doi: 10.1002/mus.10304

5. Rayman MP. Selenium and human health. Lancet. (2012) 379:1256-68. doi: 10.1016/S0140-6736(11)61452-9

6. Moghadaszadeh B, Beggs AH. Selenoproteins and their impact on human health through diverse physiological pathways. *Physiology.* (2006) 21:307–15. doi: 10.1152/physiol.00021.2006

7. Burk RF, Hill KE. Regulation of selenium metabolism and transport. Annu Rev Nutr. (2015) 35:109–34. doi: 10.1146/annurev-nutr-071714-034250

8. National Academies Press. *Dietary Reference Intakes: the Essential Guide to Nutrient Requirements.* Washington, DC: National Academies Press (2006). Available at: http://www.nap.edu/catalog/11537 (accessed August 4, 2024).

9. Esaki N, Nakamura T, Tanaka H, Soda K. Selenocysteine lyase, a novel enzyme that specifically acts on selenocysteine. Mammalian distribution and purification and properties of pig liver enzyme. *J Biol Chem.* (1982) 257:4386–91. doi: 10.1016/S0021-9258(18)34734-3

10. Bubenik JL, Miniard AC, Driscoll DM. Characterization of the UGA-recoding and SECIS-binding activities of SECIS-binding protein 2. *RNA Biol.* (2014) 11:1402–13. doi: 10.1080/15476286.2014.996472

11. Chaudière J. Biological and catalytic properties of selenoproteins. *Int J Mol Sci.* (2023) 24:10109. doi: 10.3390/ijms241210109

12. Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid. *Alexand J Med.* (2018) 54:287–93. doi: 10.1016/j.ajme.2017.09.001

13. Jackson MJ. Strategies for reducing oxidative damage in ageing skeletal muscle. *Adv Drug Deliv Rev.* (2009) 61:1363–8. doi: 10.1016/j.addr.2009.07.018

14. van Dronkelaar C, Fultinga M, Hummel M, Kruizenga H, Weijs PJM, Tieland M. Minerals and sarcopenia in older adults: an updated systematic review. *J Am Med Dir Assoc.* (2023) 24:1163–72. doi: 10.1016/j.jamda.2023.05.017

15. von Stockhausen HB. Selenium in total parenteral nutrition. *Biol Trace Elem Res.* (1988) 15:147–55. doi: 10.1007/BF02990133

16. Baptista RJ, Bistrian BR, Blackburn GL, Miller DG, Champagne CD, Buchanan L. Suboptimal selenium status in home parenteral nutrition patients with small bowel resections. J Parenter Enter Nutr. (1984) 8:542–5. doi: 10.1177/0148607184008005542

17. National Center for Health Statistics. *National Health and Nutrition Examination Survey: Analytic Guidelines, 1999–2010.* Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (2013). p. 16.

18. Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK. Radiation exposure in bone mineral density assessment. *Appl Radiat Isot: Incl Data Instrum Methods Use Agric Ind Med.* (1999) 50:215–36. doi: 10.1016/S0969-8043(98)00026-8

19. Heymsfield SB, Wang J, Heshka S, Kehayias JJ, Pierson RN. Dualphoton absorptiometry: comparison of bone mineral and soft tissue mass organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2024. 1449980/full#supplementary-material

measurements in vivo with established methods. Am J Clin Nutr. (1989) 49:1283-9. doi: 10.1093/ajcn/49.6.1283

20. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci.* (2014) 69:547–58. doi: 10.1093/gerona/glu010

21. Cheng L, Wang S. Correlation between bone mineral density and sarcopenia in US adults: a population-based study. *J Orthop Surg Res.* (2023) 18:588. doi: 10.1186/s13018-023-04034-7

22. Huang W, Deng S, Liu S, Ma Q, Cao L, Liu L, et al. Association of metabolic syndrome and sarcopenia with all-cause and cardiovascular mortality: a prospective cohort study based on the NHANES. *Front Endocrinol.* (2024) 15:1346669. doi: 10.3389/fendo.2024.1346669

23. Ahluwalia N, Dwyer J, Terry A, Moshfegh A, Johnson C. Update on NHANES dietary data: focus on collection, release, analytical considerations, and uses to inform public policy. *Adv Nutr.* (2016) 7:121–34. doi: 10.3945/an.115.009258

24. Zhu X, Cheang I, Tang Y, Shi M, Zhu Q, Gao R, et al. Associations of serum carotenoids with risk of all-cause and cardiovascular mortality in hypertensive adults. *J Am Heart Assoc.* (2023) 12:e027568. doi: 10.1161/JAHA.122.027568

25. Tang H, Zhang X, Luo N, Huang J, Zhu Y. Association of dietary live microbes and nondietary prebiotic/probiotic intake with cognitive function in older adults: evidence from NHANES. *J Gerontol A Biol Sci Med Sci.* (2024) 79:glad175. doi: 10.1093/gerona/glad175

26. Liu H, Wang Q, Dong Z, Yu S. Dietary zinc intake and migraine in adults: a cross-sectional analysis of the National Health and Nutrition Examination Survey 1999–2004. *Headache*. (2023) 63:127–35. doi: 10.1111/head.14431

27. Chen H, Tang H, Huang J, Luo N, Zhang X, Wang X. Life's essential 8 and mortality in US adults with chronic kidney disease. *am J Nephrol.* (2023) 54:516–27. doi: 10.1159/000533257

28. Perri G, Mendonça N, Jagger C, Walsh J, Eastell R, Mathers JC, et al. Dietary selenium intakes and musculoskeletal function in very old adults: analysis of the Newcastle 85+ study. *Nutrients.* (2020) 12:2068. doi: 10.3390/nu12072068

29. Liu H, Wang L, Chen C, Dong Z, Yu S. Association between dietary niacin intake and migraine among American adults: national health and nutrition examination survey. *Nutrients*. (2022) 14:3052. doi: 10.3390/nu14153052

30. Krebs-Smith SM, Pannucci TE, Subar AF, Kirkpatrick SI, Lerman JL, Tooze JA, et al. Update of the healthy eating index: HEI-2015. *J Acad Nutr Diet.* (2018) 118:1591-602. doi: 10.1016/j.jand.2018.05.021

31. Hou XZ, Lv YF, Li YS, Wu Q, Lv QY, Yang YT, et al. Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study. *Cardiovasc Diabetol.* (2024) 23:86. doi: 10.1186/s12933-024-02173-7

32. Liang J, Huang S, Jiang N, Kakaer A, Chen Y, Liu M, et al. Association between joint physical activity and dietary quality and lower risk of depression symptoms in US adults: cross-sectional NHANES study. *JMIR Public Health Surveill.* (2023) 9:e45776. doi: 10.2196/45776

33. García-Esquinas E, Carrasco-Rios M, Ortolá R, Sotos Prieto M, Pérez-Gómez B, Gutiérrez-González E, et al. Selenium and impaired physical function in US and Spanish older adults. *Redox Biol.* (2021) 38:101819. doi: 10.1016/j.redox.2020.101819

34. Beck J, Ferrucci L, Sun K, Walston J, Fried LP, Varadhan R, et al. Low serum selenium concentrations are associated with poor grip strength among older women living in the community. *Biofactors*. (2007) 29:37–44. doi: 10.1002/biof.5520290104

35. Lauretani F, Semba RD, Bandinelli S, Ray AL, Guralnik JM, Ferrucci L. Association of low plasma selenium concentrations with poor muscle strength in

older community-dwelling adults: the InCHIANTI study. Am J Clin Nutr. (2007) 86:347–52. doi: 10.1093/ajcn/86.2.347

36. Alipanah N, Varadhan R, Sun K, Ferrucci L, Fried LP, Semba RD. Low serum carotenoids are associated with a decline in walking speed in older women. J Nutr Health Aging. (2009) 13:170–5. doi: 10.1007/s12603-009-0053-6

37. Chen YL, Yang KC, Chang HH, Lee LT, Lu CW, Huang KC. Low serum selenium level is associated with low muscle mass in the community-dwelling elderly. *J Am Med Dir Assoc.* (2014) 15:807–11. doi: 10.1016/j.jamda.2014.06.014

38. Khanal P, He L, Degens H, Stebbings GK, Onambele-Pearson GL, Williams AG, et al. Dietary protein requirement threshold and micronutrients profile in healthy older women based on relative skeletal muscle mass. *Nutrients.* (2021) 13:3076. doi: 10.3390/nu13093076

39. Martin H, Aihie Sayer A, Jameson K, Syddall H, Dennison EM, Cooper C, et al. Does diet influence physical performance in community-dwelling older people? Findings from the Hertfordshire Cohort Study. *Age Ageing*. (2011) 40:181–6. doi: 10.1093/ageing/afq175

40. Moradell A, Fernández-García ÁI, Navarrete-Villanueva D, Sagarra-Romero L, Gesteiro E, Pérez-Gómez J, et al. Functional frailty, dietary intake, and risk of malnutrition. Are nutrients involved in muscle synthesis the key for frailty prevention? *Nutrients*. (2021) 13:1231. doi: 10.3390/nu13041231

41. Yeung SSY, Reijnierse EM, Deen PJJF, Trappenburg MC, Meskers CGM, Maier AB. Nutrient intake and muscle measures in geriatric outpatients. *J Am Coll Nutr.* (2021) 40:589–97. doi: 10.1080/07315724.2020.1800533

42. Schrauzer GN, Surai PF. Selenium in human and animal nutrition: resolved and unresolved issues. A partly historical treatise in commemoration of the fiftieth anniversary of the discovery of the biological essentiality of selenium, dedicated to the memory of Klaus Schwarz (1914-1978) on the occasion of the thirtieth anniversary of his death. *Crit Rev Biotechnol.* (2009) 9:2–9. doi: 10.1080/07388550902728261

43. Chapman PM. Is selenium a global contaminant of potential concern? Integr Environ Assess Manage. (2009) 5:353-4. doi: 10.1897/1551-3793-5.3.353

44. Wang N, Tan HY, Li S, Xu Y, Guo W, Feng Y. Supplementation of micronutrient selenium in metabolic diseases: its role as an antioxidant. *Oxid Med Cell Longevity.* (2017) 2017:7478523. doi: 10.1155/2017/7478523

45. Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, et al. The contribution of reactive oxygen species to sarcopenia and muscle ageing. *Exp Gerontol.* (2004) 39:17–24. doi: 10.1016/j.exger.2003.09.012

46. Papp LV, Holmgren A, Khanna KK. Selenium and selenoproteins in health and disease. Antioxid Redox Signal. (2010) 12:793–5. doi: 10.1089/ars.2009.2973

47. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. *Antioxid Redox Signal.* (2007) 9:775–806. doi: 10.1089/ars.2007.1528

48. Rederstorff M, Krol A, Lescure A. Understanding the importance of selenium and selenoproteins in muscle function. *Cell Mol Life Sci.* (2006) 63:52–9. doi: 10.1007/s00018-005-5313-y

49. Venkataraman K, Khurana S, Tai TC. Oxidative stress in aging–matters of the heart and mind. *Int J Mol Sci.* (2013) 14:17897–925. doi: 10.3390/ijms140917897

50. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. *Clin Interv Aging.* (2018) 13:757-72. doi: 10.2147/CIA.S158513

51. Gomes MJ, Martinez PF, Pagan LU, Damatto RL, Cezar MDM, Lima ARR, et al. Skeletal muscle aging: influence of oxidative stress and physical exercise. *Oncotarget.* (2017) 8:20428–40. doi: 10.18632/oncotarget.14670

52. Yao H, Fan R, Zhao X, Zhao W, Liu W, Yang J, et al. Selenoprotein W redox-regulated Ca²⁺ channels correlate with selenium deficiency-induced muscles Ca²⁺ leak. *Oncotarget.* (2016) 7:57618–32. doi: 10.18632/oncotarget. 11459

53. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. *Am J Clin Nutr.* (2011) 93:884–90. doi: 10.3945/ajcn.110.001917

54. Chernorudskiy A, Varone E, Colombo SF, Fumagalli S, Cagnotto A, Cattaneo A, et al. Selenoprotein N is an endoplasmic reticulum calcium sensor that links luminal calcium levels to redox activity. *Proc Natl Acad Sci USA*. (2020) 117:21288–98. doi: 10.1073/pnas.2003847117

55. Han SJ, Lee BC, Yim SH, Gladyshev VN, Lee SR. Characterization of mammalian selenoprotein O: a redox-active mitochondrial protein. *PLoS ONE.* (2014) 9:e95518. doi: 10.1371/journal.pone.0095518

56. Wesolowski LT, Semanchik PL, White-Springer SH. Beyond antioxidants: selenium and skeletal muscle mitochondria. *Front Vet Sci.* (2022) 9:1011159. doi: 10.3389/fvets.2022.1011159

57. Prentice RL, Mossavar-Rahmani Y, Huang Y, Van Horn L, Beresford SAA, Caan B, et al. Evaluation and comparison of food records, recalls, and frequencies for energy and protein assessment by using recovery biomarkers. *Am J Epidemiol.* (2011) 174:591–603. doi: 10.1093/aje/kwr140

58. Subar AF, Kipnis V, Troiano RP, Midthune D, Schoeller DA, Bingham S, et al. Using intake biomarkers to evaluate the extent of dietary misreporting in a large sample of adults: the OPEN study. *Am J Epidemiol.* (2003) 158:1–13. doi: 10.1093/aje/kwg092